#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

CHICA­GO — Pan­dem­ic vac­cine break­out BioN­Tech is back with more da­ta on its in­di­vid­u­al­ized mR­NA can­cer jab known as au­to­gene ce­vumer­an in the most com­mon form of pan­cre­at­ic can­cer.

While the Genen­tech-part­nered vac­cine is in two Phase II tri­als, BioN­Tech used this year’s AS­CO to present da­ta on a sin­gle-site Phase I study of the jab in pa­tients with a pan­cre­at­ic can­cer that leads to about 90% of pa­tients dy­ing with­in two years of their di­ag­no­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER